The additional presentation is approved for the treatment of pediatric patients aged 6 to 17 years with plaque psoriasis or ...

A new subgroup analysis reveals that adolescents with moderate-to-severe plaque psoriasis treated with once-daily icotrokinra ...

About one-third of psoriasis sufferers develop psoriatic arthritis, with swelling, tenderness and pain in joints, affecting daily activities and lifestyle. Psoriatic arthritis (PsA) is a chronic ...

Dr. Michael Garshick discusses recently published recommendations for cardiovascular risk screening for patients with ...

Celltrion's FDA approval of Steqeyma enhances pediatric psoriasis treatment, offering flexible dosing options for children ...

APEX shows Tremfya is the first IL-23 inhibitor to slow joint damage in psoriatic arthritis, offering early, multi-domain ...

ABOUT 5.7 MILLION men could have an autoimmune disease, according to a 2024 study published in the Journal of Clinical ...

New data from the POETYK PsA-Phase III trial, presented at the 2025 EULAR Congress, demonstrate that Bristol Myers Squibb’s Sotyktu (deucravacitinib) significantly improves joint and skin symptoms in ...

Incheon, South Korea Tuesday, June 17, 2025, 16:00 Hrs [IST] ...

Alongside the data in PsA, UCB will present at EULAR new results demonstrating that Bimzelx delivered sustained clinical responses up to three years in axSpA patients.

Icotrokinra was safe and effective for improving skin clearance among patients with at least moderate psoriasis in ...

Data from the Phase IIIb APEX study, presented at EULAR 2025, show that guselkumab (Tremfya) improved joint and skin symptoms and inhibited structural joint damage in patients with active psoriatic ...